Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209103 | 1.00 | GAA (0.46) | GAASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL6210467 | 0.81 | KMT2A (0.50) | SMN1; SMN2KMT2AMEN1POLBNPC1 | |
| SCHEMBL6210465 | 0.81 | KMT2A (0.50) | SMN1; SMN2KMT2AMEN1POLBNPC1 | |
| SCHEMBL29451601 | 0.79 | SMN1; SMN2 (0.38) | GAASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL29452096 | 0.79 | GAA (0.50) | GAASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL6318770 | 0.76 | HDAC1 (0.58) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL6210288 | 0.76 | TDP1 (0.57) | GAASMN1; SMN2MAPK1POLBALDH1A1 | |
| SCHEMBL9809394 | 0.76 | DNMT1 (0.47) | GAASMN1; SMN2KMT2AMEN1MAPK1 | |
| SCHEMBL8972018 | 0.74 | MEN1 (0.47) | SMN1; SMN2KMT2AMEN1NPC1ALDH1A1 | |
| SCHEMBL23020626 | 0.74 | NPC1 (0.47) | GAASMN1; SMN2KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1129084-B1 | THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS | GLAXO GROUP LTD (GB) | 2005-03-02 | — | — | EP | disclosed |
| US-6541492-B1 | Prevention or treatment of osteoporosis | SMITHKLINE BEECHAM CORPORATION | 2003-04-01 | — | — | US | disclosed |
| US-20020151569-A1 | PPAR gamma ligands | COLLINS JON LOREN (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1129084-A2 | PPAR GAMMA LIGANDS | GLAXO GROUP LIMITED (GB) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027832-A2 | THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS | GLAXO GROUP LIMITED (GB) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151569-A1 | PPAR gamma ligands | PPARG, PPARA, PPARD | GAA 1968/4885SMN1; SMN2 4182/4885KMT2A 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.